RecruitingSolid Tumor
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.
Sponsor: Chugai Pharmaceutical
You may not qualify if…
- ✕ Clinically significant cardiovascular or liver disease
- ✕ Treatment with investigational therapy and anti-cancer therapy within 28 days prior to initiation of study drug
- ✕ Any history of an immune-mediated Grade 4 adverse event attributed to prior cancer immunotherapy (other than asymptomatic elevation of serum amylase or lipase).
- ✕ All imAEs from prior cancer immunotherapy (other than endocrinopathy managed with replacement therapy, stable vitiligo or stable alopecia) that have not resolved completely to baseline.
- ✕ Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1 except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy
- ✕ Primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases
- ✕ Uncontrolled tumor-related pain
- ✕ Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
Where it's recruiting
Source: ClinicalTrials.gov · NCT05907980 · last updated 2026-07-28